CheckMate 214 Exploratory Biomarker Analysis: Predicting Response to Nivolumab Plus Ipilimumab in Advanced RCC

May 29-31, 2020; Online at meetings.asco.org/am
Biomarker evaluation suggests that prolonged PFS with nivo plus ipi may be associated with enhanced expression of genes involved in the tumor microenvironment and inflammatory responses; PD-L1 expression is not predictive for OS or PFS.
Format: Microsoft PowerPoint (.ppt)
File Size: 278 KB
Released: June 3, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Exelixis
Pfizer, Inc. and EMD Serono

Related Content

From Clinical Care Options (CCO), an expert video webinar on immunotherapy and targeted agents in RCC treatment

Elizabeth R. Plimack, MD, MS
Program Director
Rana R. McKay, MD Brian Rini, MD, FASCO
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: November 18, 2021 Expired: November 17, 2022

Commentary from Clinical Care Options (CCO): Maria Arcila, MD, discusses recommendations for testing for NRG1 fusions in patients with solid tumors

person default Maria E. Arcila, MD Released: November 16, 2021

Short slideset on second-generation TRK inhibitors selitrectinib and repotrectinib in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: November 9, 2021

Downloadable slideset based on discussion by Drs Plimack, McKay, and Rini on treatment options for patients with RCC, from Clinical Care Options (CCO)

Rana R. McKay, MD Elizabeth R. Plimack, MD, MS Brian Rini, MD, FASCO Released: November 1, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue